American Epilepsy Society Clinical Corner: Ganaxolone (Ztalmy®)

This AES Clinical Corner video focuses on Ganaxolone (Ztalmy®), a medication approved by the FDA on March 18, 2022, for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older.
Elia Pestana Knight, MD, the lead author of a Lancet Neurology study supporting the FDA approval and member of the AES Treatments Committee; Barry Gidal, PharmD, FAES; and John Stern, MD, FAES, discuss study details and considerations for clinicians. Dosage and administration information for ganaxolone oral suspension and other important details can be found in the FDA Prescribing Information.

[@shalabhpandit8310]

Is ganaxolone (Ztalmy)better than Laveta 750 which my cousin is taking for 7 years for seizures..twice a day?...Please suggest. Medicine is primarily levitracetum.